Literature DB >> 7549385

[Experimental and clinical study of shuanghuanglian aerosol in treating acute respiratory tract infection].

Y H Wang1, K J Xu, W S Jiang.   

Abstract

Two hundrde and two cases of acute respiratory tract infection (ARI) were treated with Shuanghuanglian (SHL) aerosol. In these cases, the majority of cases were virus infection and 64% of them was caused by the respiratory syncytial virus (RSV). The virostatic and bacteriostatic test were done in vitro by the cell culture method and it was shown that SHL could inhibit the RSV, para-influenza I-IV and 23 kinds of pathogenic bacteria such as Staphylococcus aureus etc. The bacteriostatic effect was positively correlated to the SHL concentration. Experimental study showed that SHL could enhance the NK cell activity, promote the production of alpha-interferon and raise the rate of lymphocyte transformation. The controlled observation on SHL preparation with various dosage-forms revealed that the SHL aerosol in treating early ARI showed better results than that of injections and oral liquor symptomatologically (P < 0.01). The effective rate was 96%.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7549385

Source DB:  PubMed          Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi        ISSN: 1003-5370


  3 in total

1.  Metabolomics analyses of traditional Chinese medicine formula Shuang Huang Lian by UHPLC-QTOF-MS/MS.

Authors:  Gang Xu; Yachun Shu; Yan Xu
Journal:  Chin Med       Date:  2022-05-30       Impact factor: 4.546

2.  Chinese medicine injection shuanghuanglian for treatment of acute upper respiratory tract infection: a systematic review of randomized controlled trials.

Authors:  Hongwei Zhang; Qin Chen; Weiwei Zhou; Shi Gao; Huiguang Lin; Shuifen Ye; Yihui Xu; Jing Cai
Journal:  Evid Based Complement Alternat Med       Date:  2013-03-30       Impact factor: 2.629

3.  Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients.

Authors:  Hai-Xia Su; Sheng Yao; Wen-Feng Zhao; Min-Jun Li; Jia Liu; Wei-Juan Shang; Hang Xie; Chang-Qiang Ke; Hang-Chen Hu; Mei-Na Gao; Kun-Qian Yu; Hong Liu; Jing-Shan Shen; Wei Tang; Lei-Ke Zhang; Geng-Fu Xiao; Li Ni; Dao-Wen Wang; Jian-Ping Zuo; Hua-Liang Jiang; Fang Bai; Yan Wu; Yang Ye; Ye-Chun Xu
Journal:  Acta Pharmacol Sin       Date:  2020-07-31       Impact factor: 6.150

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.